🇺🇸 FDA
Pipeline program

Placebo matching to spesolimab

1368-0140

Phase 3 small_molecule active

Quick answer

Placebo matching to spesolimab for Pyoderma gangrenosum is a Phase 3 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim International GmbH
Indication
Pyoderma gangrenosum
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials